Whereas most patients maintained humoral immunity throughout the observation period, we observed reduced cellular immune reactivity as measured by the ancestral-strain-stimulated ELISpot assay in a subset of patients. Half of the individuals (50%; 14/28) maintained cellular immunity three months after the fifth dose, despite acquiring humoral immunity.
18,745 Deaths · 89,827 Hospitalizations · 118,570 Urgent Care · 198,817 Doctor Office Visits · 2,496 Anaphylaxis · 6,335 Bell's Palsy · 2,060 Miscarriages · 9,376 Heart Attacks · 28,299 Myocarditis · 18,058 Permanently Disabled · 9,176 Thrombocytopenia · 15,106 Life Threatening · 36,584 Severe Allergic Reaction · 8,199 Shingles · 5,195 Myocarditis/Pericarditis · 3,689 Thrombocytopenia/Low Platelet ·
·
18,745 Deaths · 89,827 Hospitalizations · 118,570 Urgent Care · 198,817 Doctor Office Visits · 2,496 Anaphylaxis · 6,335 Bell's Palsy · 2,060 Miscarriages · 9,376 Heart Attacks · 28,299 Myocarditis · 18,058 Permanently Disabled · 9,176 Thrombocytopenia · 15,106 Life Threatening · 36,584 Severe Allergic Reaction · 8,199 Shingles · 5,195 Myocarditis/Pericarditis · 3,689 Thrombocytopenia/Low Platelet ·
·